<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26442/2075082X.2021.3.200921</article-id><article-id custom-type="elpub" pub-id-type="custom">systhiper-637</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group></article-categories><title-group><article-title>Особенности клиники и течения артериальной гипертонии у больных с ее различными формами</article-title><trans-title-group xml:lang="en"><trans-title>Clinical features and course of arterial hypertension in patients with its various forms</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2686-3026</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Денисова</surname><given-names>А. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Denisova</surname><given-names>A. R.</given-names></name></name-alternatives><email xlink:type="simple">nastya4358@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0479-8131</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Есаулова</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Esaulova</surname><given-names>T. E.</given-names></name></name-alternatives><email xlink:type="simple">Yestatyana@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7381-7818</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Солнцева</surname><given-names>Т. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Solntseva</surname><given-names>T. D.</given-names></name></name-alternatives><email xlink:type="simple">Tatanasolnceva372@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0060-095X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сивакова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sivakova</surname><given-names>O. A.</given-names></name></name-alternatives><email xlink:type="simple">ya.olga-siv2012@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9822-4357</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чазова</surname><given-names>И. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Chazova</surname><given-names>I. E.</given-names></name></name-alternatives><email xlink:type="simple">c34h@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Клиника «Семейная» ООО «Сеть семейных медицинских центров №2»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Family Clinic of Network of the Family Medical Centers №2</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2022</year></pub-date><volume>18</volume><issue>3</issue><fpage>140</fpage><lpage>146</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Денисова А.Р., Есаулова Т.Е., Солнцева Т.Д., Сивакова О.А., Чазова И.Е., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Денисова А.Р., Есаулова Т.Е., Солнцева Т.Д., Сивакова О.А., Чазова И.Е.</copyright-holder><copyright-holder xml:lang="en">Denisova A.R., Esaulova T.E., Solntseva T.D., Sivakova O.A., Chazova I.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/637">https://www.syst-hypertension.ru/jour/article/view/637</self-uri><abstract><p>Цель. Изучить основные факторы риска, клинико-лабораторные и инструментальные данные, сопутствующие сердечно-сосудистые заболевания (ССЗ) и ассоциированные клинические состояния у пациентов с контролируемой и неконтролируемой артериальной гипертензией (АГ), контролируемой резистентной и неконтролируемой резистентной, рефрактерной, а также вероятно резистентной и вероятно рефрактерной на основании ретроспективного анализа. Материалы и методы. В исследование включили 455 пациентов с АГ. Все пациенты разделены на 7 групп. В группу контролируемой АГ вошли 240 (52,75%) больных, контролируемой резистентной - 61 (13,4%), неконтролируемой - 10 (2,2%), неконтролируемой резистентной - 53 (11,65%), рефрактерной - 63 (13,8%), вероятно резистетной - 15 (3,3%), вероятно рефрактерной - 13 (2,9%). Во всех группах пациентов на основании анализа истории болезни проведены изучение анамнеза (оценка длительности течения и возраста начала АГ, оценка наличия ССЗ), факторов риска развития АГ (ожирение, дислипидемия, нарушение толерантности к глюкозе и гликемии натощак, гиперурикемия, отягощенный семейный анамнез по ССЗ, ранняя менопауза у женщин; частота сердечных сокращений &gt;80 уд/мин, курение), оценка лабораторных (креатинин, глюкоза, общий холестерин - ХС, ХС липопротеинов низкой плотности, ХС липопротеинов высокой плотности, триглицериды, мочевая кислота) и инструментальных (электрокардиография - ЭКГ, эхокардиография, суточное мониторирование артериального давления и ЭКГ, дуплексное сканирование брахиоцефальных артерий) методов обследования. Результаты. В данной статье представлены результаты сравнительного анализа больных контролируемой, неконтролируемой резистентной, а также рефрактерной и вероятно рефрактерной АГ. При оценке факторов риска среди пациентов с рефрактерной АГ чаще встречались молодые, некурящие и лица женского пола по сравнению с больными неконтролируемой резистентной и контролируемой АГ. Значимое преимущество в распространенности гипертрофии левого желудочка как по данным ЭКГ, так и эхокардиографии, показали больные рефрактерной АГ (p&lt;0,05). Поражение глазного дна встречали исключительно у пациентов с неконтролируемым течением АГ, 55% случаев обнаружено в группе рефрактерной АГ (p&lt;0,05). Достоверных отличий по наличию атеросклероза брахиоцефальных артерий между группами не получено. Пациенты с рефрактерной АГ значимо чаще имели сердечную недостаточность, перенесенный инсульт и транзиторную ишемическую атаку в анамнезе по сравнению с больными из группы контролируемой АГ (p&lt;0,05). Достоверной разницы по наличию хронической болезни почек, ишемической болезни сердца, сахарного диабета, фибрилляции предсердий между группами не получено. Заключение. Больные рефрактерной АГ значимо чаще имеют поражение органов-мишеней и сопутствующие ССЗ, цереброваскулярные заболевания, чем пациенты с контролируемым течением АГ.</p></abstract><trans-abstract xml:lang="en"><p>Aim. To study the main risk factors, clinical, laboratory and instrumental data, concomitant cardiovascular diseases (CVD) and associated clinical conditions in patients with controlled and uncontrolled hypertension, controlled resistant and uncontrolled resistant hypertension, refractory hypertension, and probably resistant and probably refractory hypertension based on retrospective analysis. Materials and methods. The study included 455 patients with hypertension. All patients were divided into 7 groups. The group of controlled hypertension included 240 patients (52.75%), controlled resistant hypertension - 61 (13.4%), uncontrolled hypertension - 10 (2.2%), uncontrolled resistant hypertension - 53 (11.65%), refractory hypertension - 63 (13.8%), probably resistant hypertension - 15 (3.3%), probably refractory hypertension - 13 (2.9%). Anamnesis (assessment of the duration and age of the onset of arterial hypertension, assessment of the presence of CVD), risk factors for the development of hypertension (obesity, dyslipidemia, impaired glucose tolerance and fasting glycemia, hyperuricemia, family history of CVD, early menopause in women; heart rate &gt;80 beats/min, smoking), laboratory parameters (creatinine, glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, uric acid) and instrumental methods of examination (ECG, echocardiography, clinic mean 24h BP, Holter monitoring, duplex BCA scanning) were assessed in all groups of patients based on the analysis of the medical history. Results. In this article we presented the results of a comparative analysis of patients with controlled hypertension, uncontrolled resistant hypertension, refractory and probably refractory hypertension. Patients with refractory hypertension were significantly more young, non-smokers and females compared with patients with uncontrolled resistant hypertension and controlled hypertension. Patients with refractory hypertension had greater prevalence of left ventricular hypertrophy according to ECG and echocardiography (p&lt;0.05). Fundus lesions were found exclusively in patients with uncontrolled hypertension, 55% of cases were found in the group of refractory hypertension (p&lt;0.05). There were no significant differences in the presence of BCA atherosclerosis between the groups. Patients with refractory hypertension were significantly more likely to have heart failure, a history of stroke and transient ischemic attack compared with patients from the group of controlled hypertension (p&lt;0.05). There was no significant difference in the presence of chronic kidney disease, type 2 diabetes mellitus, coronary heart disease, atrial fibrillation between the groups. Conclusion. Patients with refractory hypertension are significantly more likely to have target organ damage and concomitant cardiovascular, cerebrovascular diseases than patients with controlled hypertension.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечно-сосудистые заболевания</kwd><kwd>рефрактерная артериальная гипертония</kwd><kwd>резистентная артериальная гипертония</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cardiovascular diseases</kwd><kwd>refractory arterial hypertension</kwd><kwd>resistant arterial hypertension</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. DOI:10.1016/S0140-6736(05)17741-1</mixed-citation><mixed-citation xml:lang="en">Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. doi: 10.1016/S0140-6736(05)17741-1</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165-82. DOI:10.1001/jama.2016.19043</mixed-citation><mixed-citation xml:lang="en">Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165-82. doi: 10.1001/jama.2016.19043</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов С.А., Баланова Ю.А., Шальнова С.А., и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14 DOI:10.15829/1728-8800-2014-4-4-14</mixed-citation><mixed-citation xml:lang="en">Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterialnaia gipertoniia sredi lits 25–64 let: rasprostranennost, osvedomlennost, lechenie i kontrol. Po materialam issledovaniia ESSE. Kardiovaskuliarnaia terapiia i profilaktika. 2014;13(4):4-14 (in Russian). doi: 10.15829/1728-8800-2014-4-4-14</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fuchs FD, Frohlich FD, Massierer D, Tonelli de Oliveira FC. Abstract 5854: Prevalence of truly resistant hypertension prospectively evaluated in a clinical setting. Circulation. 2009;120:S1163.</mixed-citation><mixed-citation xml:lang="en">Fuchs FD, Frohlich FD, Massierer D, Tonelli de Oliveira FC. Abstract 5854: Prevalence of truly resistant hypertension prospectively evaluated in a clinical setting. Circulation. 2009;120:S1163.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Calhoun DA, Booth JN 3rd, Oparil S, et al. Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort. Hypertension. 2014;63:451-8. DOI:10.1161/HYPERTENSIONAHA.113.02026</mixed-citation><mixed-citation xml:lang="en">Calhoun DA, Booth JN 3rd, Oparil S, et al. Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort. Hypertension. 2014;63:451-8. doi: 10.1161/HYPERTENSIONAHA.113.02026</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Жернакова Ю.В. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31 DOI:10.26442/2075082X.2019.1.190179</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Zhernakova YuV. Clinical guidelines. Diagnostics and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31 (in Russian). doi: 10.26442/2075082X.2019.1.190179</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dudenbostel T, Siddiqui M, Oparil S, Calhoun D. Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure. Hypertension. 2016;67(6):1085-92. DOI:10.1161/HYPERTENSIONAHA.116.06587</mixed-citation><mixed-citation xml:lang="en">Dudenbostel T, Siddiqui M, Oparil S, Calhoun D. Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure. Hypertension. 2016;67(6):1085-92. doi: 10.1161/HYPERTENSIONAHA.116.06587</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cardoso CRL, Salles GF. Refractory Hypertension and Risks of Adverse Cardiovascular Events and Mortality in Patients With Resistant Hypertension: A Prospective Cohort Study. J Am Heart Assoc. 2020;9:e017634. DOI:10.1161/JAHA.120.017634</mixed-citation><mixed-citation xml:lang="en">Cardoso CRL, Salles GF. Refractory Hypertension and Risks of Adverse Cardiovascular Events and Mortality in Patients With Resistant Hypertension: A Prospective Cohort Study. J Am Heart Assoc. 2020;9:e017634. doi: 10.1161/JAHA.120.017634</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014;64:1012-21. DOI:10.1161/HYPERTENSIONAHA.114.03850</mixed-citation><mixed-citation xml:lang="en">Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014;64:1012-21. doi: 10.1161/HYPERTENSIONAHA.114.03850</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36(4):594-9. DOI:10.1161/01.hyp.36.4.594</mixed-citation><mixed-citation xml:lang="en">Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36(4):594-9. doi: 10.1161/01.hyp.36.4.594</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Velasco A, Siddiqui M, Kreps E, et al. Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes. Hypertension. 2018;72(2):343-9. DOI:10.1161/ HYPERTENSIONAHA.118.10965</mixed-citation><mixed-citation xml:lang="en">Velasco A, Siddiqui M, Kreps E, et al. Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes. Hypertension. 2018;72(2):343-9. DOI:10.1161/ HYPERTENSIONAHA.118.10965</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">van der Sande NGC, de Beus E, Bots ML, et al.; SMART study group. Apparent resistant hypertension and the risk of vascular events and mortality in patients with manifest vascular disease. J Hypertens. 2018;36(1):143-50. DOI:10.1097/HJH.0000000000001494</mixed-citation><mixed-citation xml:lang="en">van der Sande NGC, de Beus E, Bots ML, et al.; SMART study group. Apparent resistant hypertension and the risk of vascular events and mortality in patients with manifest vascular disease. J Hypertens. 2018;36(1):143-50. doi: 10.1097/HJH.0000000000001494</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Buhnerkempe MG, Botchway A, Prakash V, et al. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens. 2019;37(9):1797-804. DOI:10.1097/HJH.0000000000002103</mixed-citation><mixed-citation xml:lang="en">Buhnerkempe MG, Botchway A, Prakash V, et al. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens. 2019;37(9):1797-804. doi: 10.1097/HJH.0000000000002103</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Aucott L, Poobalan A, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension. 2005;45:1035-41.</mixed-citation><mixed-citation xml:lang="en">Aucott L, Poobalan A, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension. 2005;45:1035-41.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Guimaraes GV, de Barros Cruz LG, Fernandes-Silva MM, et al. Heated water-based exercise training reduces 24-hour ambulatory blood pressure levels in resistant hypertensive patients: a randomized controlled trial (Hex trial). Int J Cardiol. 2014;172:434-41.</mixed-citation><mixed-citation xml:lang="en">Guimaraes GV, de Barros Cruz LG, Fernandes-Silva MM, et al. Heated water-based exercise training reduces 24-hour ambulatory blood pressure levels in resistant hypertensive patients: a randomized controlled trial (Hex trial). Int J Cardiol. 2014;172:434-41.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Armario P, Oliveras A, Blanch P, et al. Refractory Hypertension. Prevalence, Associated Factors And Differences With Resistant Hypertension. J Hypertens. 2017;35(Suppl. 2):e304. DOI:10.1097/01.hjh.0000523892.30290.dd</mixed-citation><mixed-citation xml:lang="en">Armario P, Oliveras A, Blanch P, et al. Refractory Hypertension. Prevalence, Associated Factors And Differences With Resistant Hypertension. J Hypertens. 2017;35(Suppl. 2):e304. doi: 10.1097/01.hjh.0000523892.30290.dd</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Modolo R, de Faria AP, Sabbatini AR, et al. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens. 2015;9:397-402.</mixed-citation><mixed-citation xml:lang="en">Modolo R, de Faria AP, Sabbatini AR, et al. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens. 2015;9:397-402.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chedier B, Muxfeldt E, Cavalcanti A, Mares GS, et al. Refractory Hypertension: Prevalence And Patients Characteristics. J Hypertens. 2017;35(Suppl. 2):e304. DOI:10.1097/01.hjh.0000523894.07419.60</mixed-citation><mixed-citation xml:lang="en">Chedier B, Muxfeldt E, Cavalcanti A, Mares GS, et al. Refractory Hypertension: Prevalence And Patients Characteristics. J Hypertens. 2017;35(Suppl. 2):e304. doi: 10.1097/01.hjh.0000523894.07419.60</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Calhoun DA, Booth JN 3rd, Oparil S, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014;63(3):451-8. DOI:10.1161/HYPERTENSIONAHA.113.02026</mixed-citation><mixed-citation xml:lang="en">Calhoun DA, Booth JN 3rd, Oparil S, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014;63(3):451-8. doi: 10.1161/HYPERTENSIONAHA.113.02026</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012;14:7-12.</mixed-citation><mixed-citation xml:lang="en">Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012;14:7-12.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Irvin MR, Booth JN 3rd, Shimbo D, et al. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014;8:405-13. DOI:10.1016/j.jash.2014.03.003</mixed-citation><mixed-citation xml:lang="en">Irvin MR, Booth JN 3rd, Shimbo D, et al. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014;8:405-13. doi: 10.1016/j.jash.2014.03.003</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kumbhani DJ, Steg PG, Cannon CP, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Registry Investigators. Eur Heart J. 2013;34:1204-14. DOI:10.1093/eurheartj/ehs368</mixed-citation><mixed-citation xml:lang="en">Kumbhani DJ, Steg PG, Cannon CP, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Registry Investigators. Eur Heart J. 2013;34:1204-14. doi: 10.1093/eurheartj/ehs368</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32:635-43. DOI:10.1097/HJH.0000000000000051</mixed-citation><mixed-citation xml:lang="en">Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32:635-43. doi: 10.1097/HJH.0000000000000051</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Navarro-Soriano C, Martínez-García MA, Torres G, et al. Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study. The Japanese Society of Hypertension. 2019;42(11):1708-15. DOI:10.1038/s41440-019-0285-8</mixed-citation><mixed-citation xml:lang="en">Navarro-Soriano C, Martínez-García MA, Torres G, et al. Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study. The Japanese Society of Hypertension. 2019;42(11):1708-15. doi: 10.1038/s41440-019-0285-8</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
